Pentoxifylline as an Adjunct Therapy in the Treatment of Pneumonia
Conditions
Brief summary
Pentoxifylline is a xanthine-derived, commercially produced drug approved for the management of intermittent claudication in patients suffering from a chronic occlusive arterial disease of the limbs. Pentoxifylline has been documented to display anti-inflammatory and immunomodulatory effects, as well as some antithrombotic and antiviral effects. This drug has also been shown to reduce lung fibrosis in patients with COVID-19, as well as to prevent thromboembolic events. This work aims to assess the benefit of oral Pentoxifyllin supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community-acquired pneumonia
Detailed description
This is a randomized clinical trial study that will be carried out on 100 children with Community-acquired pneumonia admitted to the Pulmonology Unit, Pediatric department. Group 1: Pentoxifylline group, and group 2: Control group
Interventions
50 children with community-acquired pneumonia will receive oral pentoxifylline in tablet form as an adjunct therapy to the usual pneumonia treatment for 5 days and the control group includes 50 children with community-acquired pneumonia with the standard pneumonia treatment.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
2 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* All children aged 2 months -18 years with community-acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x-ray indicating community-acquired pneumonia
Exclusion criteria
* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorders impacting respiration i.e. genetic, metabolic, neuromuscular disorders, and children with CHD affecting the pulmonary blood flow.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Interleukin 6 | 5 days | Duration of normalization of IL-6 |
| CRP | 5 days | Duration of normalization of CRP |
| LDH | 5 days | Duration of normalization of LDH |
| D-dimer | 5 days | Duration of normalization of D-dimer |
| Respiratory distress | 3 days | Duration of improvement of respiratory distress |
| Temperature | 3 days | Duration of defeverness |
| Oxygen saturation | 3 days | Duration of normalization of hypoxia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospital stays | 14 days | Duration of stay in hospital |
| Pneumonia complications | 14 days | Occurrence of pneumonia complications |
Other
| Measure | Time frame | Description |
|---|---|---|
| Surgical intervention | 14 days | Intercostal chest tube, bronchoscope, decortication, lobectomy |
Countries
Egypt
Outcome results
None listed